A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation... by Plummer, R, Lorigan, P, Steven, N, Scott, L, Middleton, M, Wilson, R, Mulligan, E, Curtin, N, Wang, D, Dewji, R, Abbattista, A, Gallo, J, Calvert, H

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules... by Boss, D, Schwartz, G, Middleton, MR, Amakye, D, Swaisland, H, Midgley, R, Ranson, M, Danson, S, Calvert, H, Plummer, R, Morris, C, Carvajal, R, Chirieac, L, Schellens, J, Shapiro, G

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. by Plummer, R, Jones, C, Middleton, M, Wilson, R, Evans, J, Olsen, A, Curtin, N, Boddy, A, McHugh, P, Newell, D, Harris, A, Johnson, P, Steinfeldt, H, Dewji, R, Wang, D, Robson, L, Calvert, H

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. by Seymour, L, Ferry, DR, Kerr, D, Rea, D, Whitlock, M, Poyner, R, Boivin, C, Hesslewood, S, Twelves, C, Blackie, R, Schatzlein, A, Jodrell, D, Bissett, D, Calvert, H, Lind, M, Robbins, A, Burtles, S, Duncan, R, Cassidy, J